[2] R.U. Haque and
A.I. Levey, Alzheimer’s disease: A clinical perspective and future nonhuman primate research opportunities,
PNAS 116 (2019) 26224-26229.
[3] D.J. Selkoe, Alzheimer ’s disease: genes, proteins and therapy, Physiol. Rev. 81 (2001) 741–766.
[4] J. Park,
J. Seo ,
J. Won ,
H. Yeo and
Y. Ahn, Abnormal Mitochondria in a Non-human Primate Model of MPTP-induced Parkinson’s Disease: Drp1 and CDK5/p25 Signaling.
Exp Neurobiol 28 (2019) 414–424.
[5] K. Pozo and J.A. Bibb, The Emerging Role of Cdk5 in Cancer. Trends Cancer 10 (2016) 606–618.
[6] J. Seo, O. Kritskiy, L.A. Watson, S.J. Barker, D. Dey, W.K. Raja, Y.T. Lin, T. Ko, S. Cho, J. Penney, M.C. Silva, S.D. Sheridan, D. Lucente and J.F. Gusella, Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia. J. Neurosci. 37 (2017) 9917–9924.
[7] Y.L. Zheng, N.D. Amin, Y.F. Hu, P. Rudrabhatla, V. Shukla, J. Kanungo, S. Kesavapany, P. Grant, W. Albers and H.C. Pant, A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation. J. Biol. Chem. 285 (2010) 34202–34212.
[9] J. Herzog, S.M. Ehrlich, L. Pfitzer, J. Liebl, T. Frohlich, G.J. Arnold, W. Mikulits, C. Haider, A.M. Vollmar and S. Zahler, Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1alpha: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma. Oncotarget. 7 (2016) 27108-27121.
[10] J.H. Christopher, A.S. Mark and B.C. Christopher, Discovery and SAR of 2-ami-nothiazole inhibitors of CDK5/p25 as a potential treatment for Alzheimer’s disease, Bioorg. Med. Chem. Lett. 14 (2004) 5521-5525.
[11] M. Tadayon and Z. Garkani-Nejad, In silico study combining QSAR, docking and molecular dynamics simulation on 2,4- disubstituted pyridopyrimidine derivatives, J. Recept. Signal Trans. 39:2 (2019) 167-174.
[12] H. Safarizadeh and Z. Garkani-Nejad, Molecular docking, molecular dynamics simulations and QSAR studies on some of 2-arylethenylquinoline derivatives for inhibition of Alzheimer's amyloid-beta aggregation: Insight into mechanism of interactions and parameters for design of new inhibitors, J. Mol. Graph. Model. 87 (2019) 129-143.
[13] M. Shiradkar, J. Thomas, V. Kanase and R. Dighe, Studying Synergism of Methyl Linked Cyclohexyl Thiophenes with Triazole: Synthesis and Their Cdk5/P25 Inhibition Activity, Eur. J. Med. Chem. 46 (2011)2066-2074.
[15] D.M. Chhatbar, U.J. Chaube, V.K. Vyas and H.G. Bhatt, CoMFA, CoMSIA, Topomer CoMFA, HQSAR, molecular docking and molecular dynamics simulations study of triazine morpholino derivatives as mTOR inhibitors for the treatment of breast cancer, Comp. Bio. Chem. 80 (2019) 351–363.
[16] A. Khaldan, K.E. khatabi, R. El-Mernissi, A. Ghaleb, R. Hmamouchi, A. Sbai, M. Bouachrine and T. Lakhlifi, 3D-QSAR Modeling and Molecular Docking Studies of novel triazoles-quinine derivatives as antimalarial agents, J. Mater. Environ. Sci. 11 (2020) 429-443.
[17] J. Sun, S. Cai, N. Yan and H. Mei, Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis, Eur. J. Med. Chem. 45 (2010) 1008–1014.
[18] J. Zhu, Q. Yu, Y. Cai, Y. Chen, H. Liu, W. Liang and J. Jin, Theoretical Exploring Selective-Binding Mechanisms of JAK3 by 3D-QSAR, Molecular Dynamics Simulation and Free Energy Calculation. Front. Mol. Biosci. 7 (2020) 1-12.
[19] Z.Q. Yang and P.H. Sun, 3D-QSAR Study of Potent Inhibitors of Phosphodiesterase-4 Using a CoMFA Approach, Int. J. Mol. Sci. 8 (2007)714–722.
[20] Q.L. Song, P.H. Sun and W.M. Chen, Exploring 3D-QSAR for Ketolide Derivatives as Antibacterial Agents Using CoMFA and CoMSIA, Lett. Drug Des. Discov. 7 (2010) 149–159.
)